Opinion

Video

ASH 2023 Updates on Frontline Therapies in FL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Related Videos
Ashkan Emadi, MD, PhD
4 experts are featured in this series.
Peter Riedell, MD
Related Content
Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
January 6th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care